fbpx
St. Louis CyberKnife Logo

FOR PATIENTS

GET DIRECTIONS

GET IN TOUCH

(636) 496-4661

Publications

Links below provide research information about Stereotactic Radiosurgery (SRS) and Stereotactic Body Radiotherapy (SBRT).

Malignant and Benign Brain Tumors

Acoustic Neuroma/Vestibular Schwannoma

STAGED STEREOTACTIC IRRADIATION FOR ACOUSTIC NEUROMA

Cochlea Radiation Dose Correlates with Hearing Loss After Stereotactic Radiosurgery of Vestibular Schwannoma

Cyberknife Radiotherapy for Vestibular Schwannoma

Multisession Stereotactic Radiosurgery for Vestibular Schwannomas: Single-Institution Experience With 383 Cases

STAGED STEREOTACTIC IRRADIATION FOR ACOUSTIC NEUROMA

Primary, Metastatic, and Benign Brain Tumors

VISUAL FIELD PRESERVATION AFTER MULTISESSION CYBERKNIFE RADIOSURGERY FOR PERIOPTIC LESIONS

Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial

Stereotactic Radiosurgery Plus Whole-Brain
Radiation Therapy vs Stereotactic Radiosurgery
Alone for Treatment of Brain Metastases

Radiotherapeutic and surgical management for newly diagnosed brain metastasis(es): An American Society for Radiation Oncology evidence-based guideline

CYBERKNIFE RADIOSURGERY FOR BENIGN
MENINGIOMAS: SHORT-TERM RESULTS IN 199 PATIENTS

Adjuvant Whole-Brain Radiotherapy Versus Observation After Radiosurgery or Surgical Resection of One to Three Cerebral Metastases: Results of the EORTC 22952-26001 Study

Cyberknife Stereotactic Radiosurgery for Treatment of Atypical (Who Grade II) Cranial Meningiomas


Phase 3 Trials of Stereotactic Radiosurgery With or Without Whole-Brain Radiation Therapy for 1 to 4 Brain Metastases: Individual Patient Data Meta-Analysis

Motor function after stereotactic radiosurgery for brain metastases in the region of the motor cortex

‘Sun Is Setting’ on Whole-Brain Radiation for Mets

Pituitary Tumors


Hypofractionated stereotactic radiotherapy with CyberKnife for nonfunctioning pituitary adenoma: high local control with low toxicity

Stereotactic radiosurgery for pituitary adenomas: an intermediate review of its safety, efficacy, and role in the neurosurgical treatment armamentarium

HYPOFRACTIONATED CYBERKNIFE RADIOSURGERY FOR PERICHIASMATIC PITUITARY ADENOMAS: EARLY RESULTS

Radiation Therapy in the Management of Pituitary Adenomas

Prostate Cancer

Prostate Cancer

AUA Early Detection of Prostate Cancer Guidelines

The RSS White Papers for Prostate Cancer

Is Prostate Cancer Screening Right for Me

Questions to ask your Dr. at Prostate Cancer Diagnosis

Long-term Outcomes of Stereotactic Body Radiotherapy for Low-Risk and Intermediate-Risk Prostate Cancer

Low/Intermediate Risk Prostate Cancer

Long-term Outcomes of Stereotactic Body Radiotherapy for Low-Risk and Intermediate-Risk Prostate Cancer

Stereotactic body radiotherapy as treatment for organ confined low- and intermediate-risk prostate carcinoma, a 7-year study

Health-Related Quality of Life After Stereotactic Body Radiation Therapy for Localized Prostate Cancer: Results From a Multi-institutional Consortium of Prospective Trials

Stereotactic body radiotherapy for low-risk prostate cancer: five-year outcomes

Multi-institutional registry for prostate cancer radiosurgery: a prospective observational clinical trial

Cost-Effectiveness Analysis of Stereotactic Body Radiation Therapy Versus Intensity-Modulated Radiation Therapy: An Emerging Initial Radiation Treatment Option for Organ-Confined Prostate Cancer

Hypofractionated Stereotactic Body Radiotherapy in Low-Risk Prostate Adenocarcinoma

Stereotactic body radiotherapy for localized prostate cancer: Pooled analysis from a multi-institutional consortium of prospective phase II trials

Utilizing Time-Driven Activity-Based Costing to Understand the Short- and Long-Term Costs of Treating Localized, Low-Risk Prostate Cancer

SBRT for the primary treatment of localized prostate cancer: the effect of Gleason score, dose and heterogeneity of intermediate risk on outcome utilizing 2.2014 NCCN risk stratification guidelines

Patient-reported outcomes following stereotactic body radiation therapy for clinically localized prostate cancer

Stereotactic body radiation therapy for the primary treatment of localized prostate cancer

Stereotactic Body Radiation Therapy (SBRT) for clinically localized prostate cancer: the Georgetown University experience

Treatment of Prostate Cancer Local Recurrence After Whole-Gland Cryosurgery With Frameless Robotic Stereotactic Body Radiotherapy: Initial Experience

Stereotactic body radiotherapy for localized prostate cancer: disease control and quality of life at 6 years

Quality of life and toxicity after SBRT for organ-confined prostate cancer, a 7-year study

Stereotactic body radiation therapy (SBRT) for prostate cancer in men with large prostates (≥50 cm3)

Dose-escalated robotic SBRT for stage I–II prostate cancer

Comparative cost-effectiveness of stereotactic body radiation therapy versus intensity-modulated and proton radiation therapy for localized prostate cancer

Intermediate/High Risk Prostate Cancer

Genomic Classifier for Guiding Treatment of Intermediate-Risk Prostate Cancers to Dose- Escalated Image Guided Radiation Therapy Without Hormone Therapy

Hypofractionated stereotactic body radiation therapy as monotherapy for intermediate-risk prostate cancer

Stereotactic Body Radiotherapy as Boost for Organ-con ned Prostate Cancer

Stereotactic body radiotherapy with or without external beam radiation as treatment for organ confined high-risk prostate carcinoma: a six year study

A Pilot Study of Intensity Modulated Radiation Therapy with Hypofractionated Stereotactic Body Radiation Therapy (SBRT) Boost in the Treatment of Intermediate- to High-Risk Prostate Cancer

STEREOTACTIC BODY RADIOTHERAPY AS MONOTHERAPY OR POST–EXTERNAL BEAM RADIOTHERAPY BOOST FOR PROSTATE CANCER: TECHNIQUE, EARLY TOXICITY, AND PSA RESPONSE

SBRT for the primary treatment of localized prostate cancer: the effect of Gleason score, dose and heterogeneity of intermediate risk on outcome utilizing 2.2014 NCCN risk stratification guidelines

Patient-reported outcomes following stereotactic body radiation therapy for clinically localized prostate cancer

Stereotactic body radiation therapy for the primary treatment of localized prostate cancer

Stereotactic Body Radiation Therapy (SBRT) for clinically localized prostate cancer: the Georgetown University experience

Treatment of Prostate Cancer Local Recurrence After Whole-Gland Cryosurgery With Frameless Robotic Stereotactic Body Radiotherapy: Initial Experience

Stereotactic body radiotherapy for localized prostate cancer: disease control and quality of life at 6 years

Quality of life and toxicity after SBRT for organ-confined prostate cancer, a 7-year study

Stereotactic body radiation therapy (SBRT) for prostate cancer in men with large prostates (≥50 cm3)

Dose-escalated robotic SBRT for stage I–II prostate cancer

Comparative cost-effectiveness of stereotactic body radiation therapy versus intensity-modulated and proton radiation therapy for localized prostate cancer

Consult with one of our Radiation Oncologists 636.496.4660